Bristol-Myers Squibb (NYSE:BMS) posted net income of $969 million in the third quarter of 2011 and is optimistic about its pipeline of drugs approaching or in phase 3 trials as they near approval. It may have something to do with its blockbuster blood-thinning drug, Plavix, which has projected sales of $7 billion this year and […]
After Boston's Ironwood Pharmaceuticals filed Tuesday for an initial public offering, some industry observers take a stab at predicting the the five most-likely candidates to file for IPOs next. Sadly for Midwesterners, all five are from the coasts.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.